Condition: Glioblastoma · Recurrent Glioblastoma · Glioblastoma Multiforme of Brain · Sponsor: Abramson Cancer Center at Penn Medicine
* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla
This description comes directly from the study's public registry record.
Leeanne Lezotte · 8563643137 · leeanne.lezotte@pennmedicine.upenn.edu
Jeremy T Westerman, B.S. · 2159199110 · jeremy.westerman@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06613841